Suzhou Zelgen Biopharmaceutical Co Ltd has made significant progress in its clinical trials, receiving approvals for innovative cancer therapies from regulatory bodies, positioning the company for future growth in the biopharmaceutical industry.

Suzhou Zelgen Biopharmaceutical Co Ltd is navigating a financial storm in the volatile biopharmaceutical sector, with its stock price plummeting due to investor skepticism and capital outflows.